News ArticleAster DM Quality Care Q2 FY27 Profit Rises 34% to INR 281 Crore on 19% Revenue Growth
Company reports 68% occupancy and 12% patient volume increase in first quarter post-merger; Advances in clinical capabilities and accreditations noted
Aster DM Quality Care Limited reported a 19% year-on-year revenue increase to INR 2,829 crore and a 34% rise in normalized PAT to INR 281 crore for Q2 FY27, marking its first quarter as a merged entity. The company achieved 23% ROCE and saw strong patient volume growth and clinical advancements during the quarter.
Aster DM Quality Care Limited
General / Other
Aster DM Quality Care Limited posted consolidated revenue of INR 2,829 crore and normalized profit after tax of INR 281 crore for the quarter ending September 30, 2026, reflecting 19% and 34% year-on-year growth respectively in its first quarter post-merger.
The company’s return on capital employed rose to 23%, an increase of 152 basis points compared to the previous year.
Patient volumes grew 12% year-over-year to 2.2 million patients served, with hospital occupancy improving by 335 basis points to 68%.
Significant growth was seen in complex procedures including robotic surgeries (up 39%), kidney transplants (up 31%) and joint replacements (up 29%).
Medical Value Travel revenue increased by 36% year-on-year, driven by markets including Maldives, GCC countries, West Africa, and other MENA regions.
Emerging hospitals including Kasargod and Nagarcoil showed robust 61% growth, while mature hospitals contributed 73% of revenue with an 18% growth.
Highlights
- Q2 FY27 revenue reached INR 2,829 crore, a 19% increase year-on-year.
- Normalized profit after tax increased 34% to INR 281 crore, with a margin of 10%.
- Total patient volume increased 12% to 2.2 million, with occupancy rising to 68%.
- The company completed its first 100 days post-merger and integrated teams and systems successfully.
- CARE Hospitals received JCI accreditation; MIMS Kasargod received NABH accreditation within its first year.
- Three Centres of Excellence launched to enhance specialised care offerings across various hospitals.
Key Data Snapshot
What happened
- Aster DM Quality Care Limited reported its unaudited financial results for Q2 FY27, marking the first quarter after the merger of Aster DM Healthcare and Quality Care India.
- The company recorded a 19% increase in consolidated revenue to INR 2,829 crore and a 34% rise in normalized profit after tax to INR 281 crore.
- Patient volumes increased by 12% annually, with hospital occupancy improving to 68%.
Key details
- Return on capital employed (ROCE) rose to 23%, up by 152 basis points year-on-year.
- Medical Value Travel (MVT) revenue grew 36% year-on-year, driven by markets in Maldives, GCC, West Africa, and other MENA countries.
- Emerging hospitals, including Kasargod and Nagarcoil, grew revenue by 61%, while mature hospitals contributed approximately 73% of total hospital revenue with 18% growth year-on-year.
Operational performance
- Complex clinical procedures saw strong growth: robotic surgeries increased by 39%, kidney transplants by 31%, and joint replacements by 29%.
- The company performed several firsts in clinical procedures, including adaptive Deep Brain Stimulation for Parkinson’s disease and Kerala’s first liquid nitrogen cryoablation for breast fibroadenomas.
- Three Centres of Excellence were launched to enhance specialised care in robotic spine surgery, cancer treatment, and fetal medicine.
Strategic context
- The quarter was the first full quarter operating as a merged entity combining four healthcare brands: Aster DM, CARE Hospitals, Evercare, and KIMSHEALTH.
- The integration focused on team alignment and operational excellence to serve 2.2 million patients with improved healthcare delivery.
- The company continues to expand network capacity and invest in clinical talent, infrastructure, and technology for sustainable growth.
Regulatory and governance context
- CARE Hospitals, HITEC City, Hyderabad, received Joint Commission International (JCI) accreditation during the quarter.
- MIMS Kasargod achieved National Accreditation Board for Hospitals & Healthcare Providers (NABH) accreditation within a year of commencing operations.
- The company was recognized at the Global ESG Awards 2026 for supporting economically weaker sections, renewable energy integration, and CSR excellence.
Highlights
- Q2 FY27 revenue reached INR 2,829 crore, a 19% increase year-on-year.
- Normalized profit after tax increased 34% to INR 281 crore, with a margin of 10%.
- Total patient volume increased 12% to 2.2 million, with occupancy rising to 68%.
- The company completed its first 100 days post-merger and integrated teams and systems successfully.
- CARE Hospitals received JCI accreditation; MIMS Kasargod received NABH accreditation within its first year.
- Three Centres of Excellence launched to enhance specialised care offerings across various hospitals.
Disclosures
- SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Source Information
More News on General / Other
View allLatest corporate announcements and market updates in General / Other.
Manali Petrochemicals Posts Rs. 414.37 Crore Consolidated Income for Q2 Ending September 2026 with Stable Profits
Manali Petrochemicals Limited announced its unaudited consolidated financial results for the quarter ended 30th September 2026, reporting a total income of Rs. 414.37 crore and profit before tax of Rs. 85.30 crore, with steady standalone financial performance and increased business activity.
Read Full Story
Gala Precision Engineering Limited Confirms Proper Utilization of Rs 1,353.40 Million IPO Proceeds in Q2 2026
Gala Precision Engineering Limited's Monitoring Agency report for the quarter ended September 30, 2026, states full compliance in the utilization of Rs 1,353.40 million raised through its Initial Public Offer. The funds have been deployed as disclosed in the offer document, covering a new manufacturing facility in Tamil Nadu, capital expenditure in Maharashtra, repayment of borrowings, and general corporate purposes.
Read Full Story
NGL Fine-Chem Invests in 3.10 MW Solar and 3.60 MW Wind Projects for Long-Term Renewable Energy Supply
NGL Fine-Chem Limited's Board approved entering into power purchase agreements for renewable energy from a 3.10 MW solar and a 3.60 MW wind power project in Maharashtra, alongside subscribing to 26% and 22.28% equity stakes respectively in their special purpose vehicles.
Read Full Story
